Having trouble accessing articles? Reset your cache.

Penn emerges from Novartis alliance a prolific source of cell, gene therapies

University of Pennsylvania is closing out its seven year landmark CAR T partnership with Novartis with a stable of collaborations and a list of new directions for CARs, both in and out of cancer.

Penn’s 2012 deal with Novartis AG (NYSE:NVS; SIX:NOVN) led to the first approved chimeric antigen receptor (CAR) T cell therapy for cancer Kymriah tisagenlecleucel in 2017, now marketed

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE